← Back to Search
Treatment With Indinavir, Zidovudine, And Lamivudine In Adults With Human Immunodeficiency Virus Infection And Prior Antiretroviral Therapy.
R. Gulick, J. Mellors, D. Havlir, J. Eron, C. Gonzalez, D. McMahon, D. Richman, F. Valentine, L. Jonas, A. Meibohm, E. Emini, J. Chodakewitz
Published 1997 · Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
BACKGROUND The new protease inhibitors are potent inhibitors of the human immunodeficiency virus (HIV), and in combination with other antiretroviral drugs they may be able to cause profound and sustained suppression of HIV replication. METHODS In this double-blind study, 97 HIV-infected patients who had received zidovudine treatment for at least 6 months and had 50 to 400 CD4 cells per cubic millimeter and at least 20,000 copies of HIV RNA per milliliter were randomly assigned to one of three treatments for up to 52 weeks: 800 mg of indinavir every eight hours; 200 mg of zidovudine every eight hours combined with 150 mg of lamivudine twice daily; or all three drugs. The patients were followed to monitor the occurrence of adverse events and changes in viral load and CD4 cell counts. RESULTS The decrease in HIV RNA over the first 24 weeks was greater in the three-drug group than in the other groups (P<0.001 for each comparison). RNA levels decreased to less than 500 copies per milliliter at week 24 in 28 of 31 patients in the three-drug group (90 percent), 12 of 28 patients in the indinavir group (43 percent), and none of 30 patients in the zidovudine-lamivudine group. The increase in CD4 cell counts over the first 24 weeks was greater in the two groups receiving indinavir than in the zidovudine-lamivudine group (P< or =0.01 for each comparison). The changes in the viral load and the CD4 cell count persisted for up to 52 weeks. All the regimens were generally well tolerated. CONCLUSIONS In most HIV-infected patients with prior antiretroviral therapy, the combination of indinavir, zidovudine, and lamivudine reduces levels of HIV RNA to less than 500 copies per milliliter for as long as one year.
This paper references
Lymphocyte Survival in Men treated with X-rays for Ankylosing Spondylitis
K. Buckton (1967)
Rational design of peptide-based HIV proteinase inhibitors.
N. Roberts (1990)
Analyzing laboratory marker changes in AIDS clinical trials.
J. Dawson (1991)
Lifespan of human lymphocyte subsets defined by CD45 isoforms
C. Michie (1992)
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine
Q. Gao (1993)
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
R. Schinazi (1993)
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
M. Tisdale (1993)
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.
J. Vacca (1994)
Comparing Treatment Groups on the Basis of Slopes, Areas-Under-the-Curve, and other Summary Measures
J. Dawson (1994)
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
J. Condra (1995)
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
D. Kempf (1995)
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.
M. Markowitz (1995)
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
R. Schuurman (1995)
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
J. Eron (1995)
Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme
E. E. Kim (1995)
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.
S. Danner (1995)
Treatment with lamivudine , zidovudine , or both in HIV - positive patients with 200 to 500 CD 4 cells per cubic millimeter
JJ Eron (1995)
Antiretroviral activity of the oral protease inhibitor, MK-639, in p24 antigenemic, HIV-1 infected patients with Ͻ500 CD4/mm 3
J Mellors (1995)
The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
D. Katzenstein (1996)
Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
D. Kuritzkes (1996)
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
A. Collier (1996)
Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.
T. O'Brien (1996)
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
W. O'brien (1996)
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
J. Darbyshire (1996)
Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.
R. Coombs (1996)
Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma
J. Mellors (1996)
Lamivudine Plus Zidovudine Compared with Zalcitabine Plus Zidovudine in Patients with HIV Infection
J. Bartlett (1996)
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
S. Hammer (1996)
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
A. Molla (1996)
Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy
S. Welles (1996)
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
J. Condra (1996)
A trial comparing nucleoside monotherapy with combination therapy in HIV - infected adults with CD 4 cell counts from 200 to 500 per cubic millimeter
DA Katzenstein (1996)
The relation of vi - rologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV - infected adults with 200 to 500 CD 4 cells per cubic millimeter
NA Roberts (1996)
Treatment of human immunodeficiency virus infection with saquinavir , zidovudine , and zalcita - bine
JD Dawson (1996)
Changes in plasma HIV - 1 RNA and CD 4 lymphocyte counts and the risk of progression to AIDS
SL Welles (1996)
Reductions in HIV - 1 disease progression for AZT / 3 TC relative to control treatments : a meta analysis
Antiretroviral activity of the oral protease inhibitor , MK - 639 , in p 24 antigenemic , HIV - 1 infected patients with 500 CD 4 / mm 3
This paper is referenced by
Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors
M. Hamed (2021)
Guangdi Li (2021)
Dual Antiretroviral Therapy—All Quiet Beneath the Surface?
B. V. van Welzen (2021)
Understanding the Struggle Between Viruses and the Immune System: A Quintessential Grand Challenge
M. Clerici (2021)
Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening
Anjela Manandhar (2021)
Retrospective trend analysis of HIV viral load suppression among antiretroviral therapy clients in Bauchi State, Nigeria
Z. G. Ibrahim (2021)
Nanotechnology for virus treatment
Jiarong Zhou (2021)
Oral administration of tipranavir with long-chain triglyceride results in moderate intestinal lymph targeting but no efficient delivery to HIV-1 reservoir in mesenteric lymph nodes.
Yenju Chu (2021)
The Importance of Glycans of Viral and Host Proteins in Enveloped Virus Infection
Yuqing Li (2021)
Exosomes in HIV infection
Jing Chen (2021)
Potential Utility of Natural Killer Cells for Eliminating Cells Harboring Reactivated Latent HIV-1 Following the Removal of CD8+ T Cell-Mediated Pro-Latency Effect(s)
G. Khoury (2021)
STING and cGAS gene expressions were downregulated among HIV-1-infected persons after antiretroviral therapy
Lorena Leticia Peixoto de Lima (2021)
Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo
Courtney L. Finch (2021)
Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach.
Chaolong Qin (2020)
Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets
B. Castle (2020)
An Overview of Piperazine Scaffold as Promising Nucleus for Different Therapeutic Targets.
Anjali Sharma (2020)
The crosstalk between antiretrovirals pharmacology and HIV drug resistance
A. Giacomelli (2020)
Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing
R. Fernández-García (2020)
Novel Antiretroviral Agents
M. Cambou (2020)
Regio‐ and Diastereoselective Rhodium‐Catalyzed Allylic Substitution with Unstabilized Benzyl Nucleophiles
Debasis Pal (2020)
30 Jahre ART: Vom Todesurteil zur chronischen Erkrankung
Julian Hafner (2020)
HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes
T. Xiao (2020)
Antiretroviral Long-Term Efficacy and Resistance of Lopinavir/Ritonavir Plus Lamivudine in HIV-1-Infected Treatment-Naïve Patients (ALTERLL): 144-Week Results of a Randomized, Open-Label, Non-Inferiority Study From Guangdong, China
P. Guo (2020)
Anti-HIV-1 Antibodies: An Update
Wanwisa Promsote (2020)
Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection
Vanessa Monteil (2020)
Bibliometric analysis of the most cited articles in urolithiasis
Komathy Murugathas (2020)
Simultaneous Optimization of Drug Combination Dose‐Ratio Sequence with Innovative Design and Active Learning
Aiting Wang (2020)
Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists.
J. Siliciano (2020)
Neurotoxicity of HIV-1 Tat is attributed to its penetrating property
Xiaoli Tang (2020)
Virus – On the Edge of Art and Science, Human Beings, and Nature
T. Zhou (2020)
In Situ Detection of Endogenous HIV Activation by Dynamic Nuclear Polarization NMR and Flow Cytometry
Sarah A. Overall (2020)
Modifications at the C(5) position of pyrimidine nucleosides
W. Kozak (2020)See more